Dr. Mihaela Druta, MD

Dr. Druta practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Druta's NPI, 1073707170, was assigned on August 31, 2007. Dr. Druta graduated from Carol Davila University of Medicine and Pharmacy in 1999. Dr. Druta holds Florida license 105325.

Dr. Druta's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Druta's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Druta to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Druta practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Druta's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Druta is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Druta's licenses on file in 2 states: Florida and Texas.

Dmand AI lists breast cancer, colorectal cancer, multiple myeloma and prostate cancer among the conditions Dr. Druta treats.

CMS data shows 319 Medicare services from Dr. Druta across 5 procedure codes in 2024, for 130 Medicare patients. Medicare paid $21,530 for them.

CMS counts 130 Medicare patients who saw Dr. Druta in 2024. The largest group is 65 to 74, with 59 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Druta's median patient age at 68, with 54% women.

In 2024, Dr. Druta wrote 42 Medicare Part D claims for 20 patients. 83% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $129,984 in total drug cost. In 2023, CMS named 14 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Druta for performance year 2024, reported as part of a group. Dr. Druta accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Druta as offering telehealth.

Dmand AI links 29 papers to Dr. Druta, published from 2013 to 2025. 2020 was the busiest year, with 8. The most frequent topics are Sarcoma, Antigens, Neoplasm and Membrane Proteins. Dr. Druta has published most often in Cancer Control. Dr. Druta's most frequent co-authors are Andrew S. Brohl, MD, Dejka M. Araujo, MD and Damon R. Reed, MD.

Dmand AI links Dr. Druta to 16 clinical trials, 6 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Histiocytoma, Sarcoma and Liposarcoma, Myxoid. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Druta that name 3 trials.

CMS Open Payments shows 149 general payments to Dr. Druta from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 44% of the total. Eisai Inc. paid the most, $32,237. It also lists 6 research payments totaling $7,849 from 2016 to 2025, naming 3 clinical trials.

Dr. Druta graduated from Carol Davila University of Medicine and Pharmacy in 1999.

Dr. Druta is in network with 9 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.